Novel 18β-glycyrrhetinic acid analogues as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenases

被引:69
作者
Su, XD
Lawrence, H
Ganeshapillai, D
Cruttenden, A
Purohit, A
Reed, MJ
Vicker, N
Potter, BVL [1 ]
机构
[1] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England
[2] Univ Bath, Sterix Ltd, Bath BA2 7AY, Avon, England
[3] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Sch Med, Sterix Ltd, London W2 1NY, England
关键词
D O I
10.1016/j.bmc.2004.06.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Extensive structural modifications to the 18beta-glycyrrhetinic acid template are described and their effects on the SAR of the 11beta-hydroxysteroid dehydrogenase isozymes type 1 and 2 from the rat are investigated. Isoform selective inhibitors have been discovered and compound 7 N-(2-hydroxyethyl)-3beta-hydroxy-11-oxo-18beta-olean-12-en-30-oic acid amide is highlighted as a very potent selective inhibitor of 11beta-hydroxysteroid dehydrogenase 2 with an IC50 = 4 pM. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4439 / 4457
页数:19
相关论文
共 35 条
[1]
Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice [J].
Alberts, P ;
Engblom, L ;
Edling, N ;
Forsgren, M ;
Klingström, G ;
Larsson, C ;
Rönquist-Nii, Y ;
Öhman, B ;
Abrahmsén, L .
DIABETOLOGIA, 2002, 45 (11) :1528-1532
[2]
Effects of the 11β-hydroxysteroid dehydrogrenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes [J].
Andrews, RC ;
Rooyackers, O ;
Walker, BR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (01) :285-291
[3]
Glutamate-115 renders specificity of human 11β-hydroxysteroid dehydrogenase type 2 for the cofactor NAD+ [J].
Arnold, P ;
Tam, S ;
Yan, L ;
Baker, ME ;
Frey, FJ ;
Odermatt, A .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2003, 201 (1-2) :177-187
[4]
Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs.: Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1 [J].
Barf, T ;
Vallgårda, J ;
Emond, R ;
Häggström, C ;
Kurz, G ;
Nygren, A ;
Larwood, V ;
Mosialou, E ;
Axelsson, K ;
Olsson, R ;
Engblom, L ;
Edling, N ;
Rönquist-Nii, Y ;
Öhman, B ;
Alberts, P ;
Abrahmsén, L .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) :3813-3815
[5]
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[6]
Expression of 11βHSD-2 in human adrenal cortical carcinoma and adenoma [J].
Coulter, CL ;
Smith, RE ;
Stowasser, M ;
Sasano, H ;
Krozowski, ZS ;
Gordon, RD .
ENDOCRINE RESEARCH, 1998, 24 (3-4) :875-876
[7]
Type 1 11β-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets [J].
Davani, B ;
Khan, A ;
Hult, M ;
Mårtensson, E ;
Okret, SE ;
Efendic, S ;
Jörnvall, H ;
Oppermann, UCT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (45) :34841-34844
[8]
Extensive personal experience - Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess [J].
Dave-Sharma, S ;
Wilson, RC ;
Harbison, MD ;
Newfield, R ;
Azar, MR ;
Krozowski, ZS ;
Funder, JW ;
Shackleton, CHL ;
Bradlow, HL ;
Wei, JQ ;
Hertecant, J ;
Moran, A ;
Neiberger, RE ;
Balfe, JW ;
Fattah, A ;
Daneman, D ;
Akkurt, HI ;
De Santis, C ;
New, MI .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (07) :2244-2254
[9]
In the search for specific inhibitors of human 11β-hydroxysteroid-dehydrogenases (11β-HSDs):: chenodeoxycholic acid selectively inhibits 11β-HSD-I [J].
Diederich, S ;
Grossmann, C ;
Hanke, B ;
Quinkler, M ;
Herrmann, M ;
Bähr, V ;
Oelkers, W .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 142 (02) :200-207
[10]
LOCALIZATION OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TISSUE SPECIFIC PROTECTOR OF THE MINERALOCORTICOID RECEPTOR [J].
EDWARDS, CRW ;
BURT, D ;
MCINTYRE, MA ;
DEKLOET, ER ;
STEWART, PM ;
BRETT, L ;
SUTANTO, WS ;
MONDER, C .
LANCET, 1988, 2 (8618) :986-989